Obesity drug RAY1225 put through drug interaction tests
NCT ID NCT07362030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study checks if a new obesity drug, RAY1225, changes how the body processes common medicines like warfarin, atorvastatin, metformin, and digoxin. About 32 healthy adults will take RAY1225 along with these drugs to measure blood levels and watch for side effects. The goal is to gather safety information, not to treat obesity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dongguan People's Hospital
Dongguan, China